Cellino Biotech ^Company

This project by Cellino Biotech will use the company's proprietary NanoLaze gene-editing platform on the ground to deliver CRISPR/Cas9-modified genes to induced pluripotent stem cells (iPSCs) for growth studies in space. The research team will monitor the proliferation of the gene-edited iPSCs in space to determine if the cells maintain their pluripotentency through multiple cell divisions in microgravity. Results could help lead to solutions to address the current technology barrier that limits the ability to generate the 200 to 500 million stem cells needed for cell-based therapies to treat diseases in patients on Earth.